Takayuki Yoshioka

Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.

Takeshi Itoh, Masatoshi Tanioka, Hiroki Yoshida et al. · PubMed · 1998 · 878 citations

Medicine, Cancer Biology, Oncology +15

Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2):  <i>N</i>-Sulfonylamino Acid Derivatives

Yoshinori Tamura, Fumihiko Watanabe, Takuji Nakatani et al. · Journal of Medicinal Chemistry · 1998 · 283 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells <i>in vivo</i>. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of <i>in vivo</i> immunity.

H Fujiwara, Masayuki Fukuzawa, Takayuki Yoshioka et al. · The Journal of Immunology · 1984 · 155 citations

Life Sciences, Immunology, Oncology +17

Antitumor Efficacy of Hypothemycin, A New Ras‐signaling Inhibitor

Hidekazu Tanaka, Kazuyo Nishida, Kenji Sugita et al. · Japanese Journal of Cancer Research · 1999 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

Fumihiko Kanzawa, Fumiaki Koizumi, Yasuhiro Koh et al. · PubMed · 2001 · 59 citations

Medicine, Oncology, Pharmacology +17